Loxo Oncology, Inc. (NASDAQ:LOXO) was the recipient of unusually large options trading activity on Monday. Investors bought 552 call options on the company. This represents an increase of approximately 617% compared to the typical volume of 77 call options.

Loxo Oncology (NASDAQ:LOXO) opened at $86.14 on Thursday. Loxo Oncology has a one year low of $30.51 and a one year high of $95.92. The stock has a market cap of $2,604.56, a P/E ratio of -14.78 and a beta of 2.54.

In other Loxo Oncology news, VP Jennifer Burstein sold 1,700 shares of the firm’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $87.19, for a total transaction of $148,223.00. Following the completion of the transaction, the vice president now owns 1,700 shares in the company, valued at $148,223. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Avi Z. Naider sold 5,000 shares of the firm’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $90.00, for a total transaction of $450,000.00. Following the transaction, the director now owns 144,118 shares of the company’s stock, valued at approximately $12,970,620. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,614,555 shares of company stock valued at $124,567,942. Corporate insiders own 27.80% of the company’s stock.

Several large investors have recently bought and sold shares of LOXO. Quantbot Technologies LP bought a new position in shares of Loxo Oncology in the third quarter valued at approximately $122,000. Ameritas Investment Partners Inc. raised its stake in shares of Loxo Oncology by 31.3% in the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 419 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Loxo Oncology by 4,388.0% in the second quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 2,194 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Loxo Oncology in the third quarter valued at approximately $212,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Loxo Oncology in the second quarter valued at approximately $228,000. Institutional investors own 99.98% of the company’s stock.

A number of research analysts have commented on the stock. BidaskClub upgraded shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Zacks Investment Research cut shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. William Blair assumed coverage on shares of Loxo Oncology in a research note on Tuesday, November 28th. They set an “outperform” rating for the company. Citigroup cut their price target on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. Finally, JMP Securities upgraded shares of Loxo Oncology from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $77.18 to $95.00 in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Loxo Oncology currently has an average rating of “Buy” and an average target price of $90.57.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/28/traders-purchase-high-volume-of-call-options-on-loxo-oncology-loxo.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Receive News & Stock Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related stocks with our FREE daily email newsletter.